Literature DB >> 8221568

Cervical cytopathology. An evaluation of its accuracy based on cytohistologic comparison.

L DiBonito1, G Falconieri, G Tomasic, I Colautti, D Bonifacio, S Dudine.   

Abstract

BACKGROUND: Although Papanicolaou cytology represents the most effective technique to prevent and detect precancerous conditions of the uterine cervix, its false-negative yield is still a reason of concern among pathologists and gynecologists.
METHODS: Because histologic control is one of the best ways to assess the accuracy of cytology diagnosis, the authors have investigated 1000 women who had cervical smears and tissue sampling obtained during the same colposcopic evaluation between 1987 and 1990.
RESULTS: Out of 1000 cases (average age, 34.6 years; range, 14-80 years), 918 had adequate, 62 had less than optimal, and 10 had unsatisfactory samples. Cytology unsatisfactory and less than optimal cases as well as inadequate histology cases have been disregarded from all calculations. After histologic comparison, confirmed negatives were 622 of 918 (67.8%). Cytologic diagnoses of cervical intra-epithelial neoplasia (CIN) I were 96, of CIN II were 44, of CIN III, inclusive of carcinoma in situ, were 39, and of invasive carcinoma were 2. Atypical cases were 56. The overall sensitivity was 76.3%, with group sensitivity rates increasing directly with CIN grade. Positive predictive value was 80.2%. Specificity was 93.0%, and negative predictive value was 91.3%. False-negatives were 59 of 681 (8.7%), basically due to sampling errors. Among true-positives, there was 1 category discrepancy in 30 cases (mostly undercalled or overcalled CIN II) and 2 category discrepancies in 4 cases.
CONCLUSIONS: Cervical cytology has an overall accuracy close to that reported in studies employing indirect control methods, such as patient follow-up. Higher sensitivity rates emerged for CIN II, CIN III, and cervical carcinoma. Our figures of sensitivity and specificity may represent a useful reference source for future studies dealing with quality control in cervical cytopathology.

Entities:  

Mesh:

Year:  1993        PMID: 8221568     DOI: 10.1002/1097-0142(19931115)72:10<3002::aid-cncr2820721023>3.0.co;2-4

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  7 in total

1.  Fourier transform infrared (FTIR) spectral mapping of the cervical transformation zone, and dysplastic squamous epithelium.

Authors:  B R Wood; L Chiriboga; H Yee; M A Quinn; D McNaughton; M Diem
Journal:  Gynecol Oncol       Date:  2004-04       Impact factor: 5.482

2.  Papanicolaou test in the detection of high-grade cervical lesions: a re-evaluation based on cytohistologic non-correlation rates in 356 concurrently obtained samples.

Authors:  Bhavini Carns; Oluwole Fadare
Journal:  Int J Clin Exp Pathol       Date:  2008-01-01

3.  [Correlation of cervical cytology and histology].

Authors:  K Marquardt
Journal:  Pathologe       Date:  2011-11       Impact factor: 1.011

4.  Evaluation of a cervical cytology device (cell-sweep) based on comparison to colposcopic findings.

Authors:  C Kieswetter; E Hernandez; L Anderson; P B Heller
Journal:  J Natl Med Assoc       Date:  2001-11       Impact factor: 1.798

5.  Estimating the accuracy of anal cytology in the presence of an imperfect reference standard.

Authors:  William C Mathews; Edward R Cachay; Joseph Caperna; Amy Sitapati; Bard Cosman; Ian Abramson
Journal:  PLoS One       Date:  2010-08-19       Impact factor: 3.240

6.  Comparative accuracy of anal and cervical cytology in screening for moderate to severe dysplasia by magnification guided punch biopsy: a meta-analysis.

Authors:  Wm Christopher Mathews; Wollelaw Agmas; Edward Cachay
Journal:  PLoS One       Date:  2011-09-19       Impact factor: 3.240

Review 7.  Relative accuracy of cervical and anal cytology for detection of high grade lesions by colposcope guided biopsy: a cut-point meta-analytic comparison.

Authors:  Edward R Cachay; Wollelaw Agmas; William C Mathews
Journal:  PLoS One       Date:  2012-07-25       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.